Abstract:Peroxisome proliferator-activated receptor gamma (PPAR-γ) serves as a nuclear receptor with a pivotal function in governing diverse facets of metabolic processes. In diabetes, the prime physiological role of PPAR-γ is to enhance insulin sensitivity and regulate glucose metabolism. Although PPAR-γ agonists such as Thiazolidinediones are effective in addressing diabetes complications, it is vital to be mindful that they are associated with substantial side effects that could potentially give rise to health challenges. The recent surge in the discovery of selective modulators of PPAR-γ inspired us to formulate an integrated computational strategy by leveraging the promising capabilities of both machine learning and in silico drug design approaches. In pursuit of our objectives, the initial stage of our work involved constructing an advanced machine learning classification model, which was trained utilizing chemical information and physicochemical descriptors obtained from known PPAR-γ modulators. The subsequent application of machine learning-based virtual screening, using a library of 31,750 compounds, allowed us to identify 68 compounds having suitable characteristics for further investigation. In total of four compounds were identified and the most favorable configurations were complemented with docking scores ranging from −8.0 to −9.1 kcal/mol. Additionally, the compounds engaged in hydrogen bond interactions with essential conserved residues including His323, Leu330, Phe363, His449 and Tyr473 that describe the ligand binding site. The stability indices investigated herein for instance root-mean-square fluctuations in the backbone atoms indicated higher mobility in the region of orthosteric site in the presence of agonist with the deviation peaks in the range of 0.07–0.69 nm, signifying moderate conformational changes. The deviations at global level revealed the average values of 0.25–0.32 nm. In conclusion, our identified hits particularly, CHEMBL-3185642 and CHEMBL-3554847 presented with outstanding results and highlighted the stable conformation within the orthosteric site of PPAR-γ to positively modulate the activity.

Identification of Novel PPARα/γ Dual Agonists by Pharmacophore Screening, Docking Analysis, ADMET Prediction and Molecular Dynamics Simulations.

Identification of Novel PPARα/γ Dual Agonists by Virtual Screening, ADMET Prediction and Molecular Dynamics Simulations.

Identification of Novel PPAR?/? Dual Agonists by Virtual Screening of Specs Database

Identification of Novel PPAR alpha/gamma Dual Agonists by Virtual Screening of Specs Database

MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism

Exploring Dual Agonists for PPARα/γ Receptors Using Pharmacophore Modeling, Docking Analysis and Molecule Dynamics Simulation.

Identification of a novel PPARγ modulator with good anti-diabetic therapeutic index via structure-based screening, optimization and biological validation

Scaffold-based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors.

Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold

Virtual identification of novel peroxisome proliferator-activated receptor (PPAR) α/δ dual antagonist by 3D-QSAR, molecule docking and molecule dynamics simulation.

Uncovering PPAR-γ agonists: An integrated computational approach driven by machine learning

Three-in-one Agonists for PPAR-α, PPAR-γ, and PPAR-δ from Traditional Chinese Medicine

Molecular dynamics articulated multilevel virtual screening protocol to discover novel dual PPAR α/γ agonists for anti-diabetic and metabolic applications

Virtual Identification Of Novel Ppar Alpha/Gamma Dual Agonists By Scaffold Hopping Of Saroglitazar

Design, Synthesis, and Biological Evaluation of Novel Pan Agonists of FFA1, PPARγ and PPARδ.

Design, molecular docking and dynamics simulations of PPARs pan agonists

Ligand Based Drug Designing of Molecular Target PPARγ/AT1R Through CDOCKER and ADMET Prediction

Virtual Screening, Docking, Synthesis and Bioactivity Evaluation of Thiazolidinediones As Potential PPARγ Partial Agonists for Preparation of Antidiabetic Agents

Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.

Virtual screening, molecular dynamics, density functional theory and quantitative structure activity relationship studies to design peroxisome proliferator-activated receptor-γ agonists as anti-diabetic drugs

Design, Synthesis, and Biological Evaluation of Novel Dual FFA1 (gpr40)/pparδ Agonists As Potential Anti-Diabetic Agents.